The Centers for Disease Control and Prevention (CDC) announced its recommendations for the 2024 immunization schedule for adults 19 years or older and it has undergone significant vaccine-specific changes. Specifically, the Advisory Committee on Immunization Practices (ACIP) made notable updates including new and revised recommendations for respiratory syncytial virus vaccines (RSV), influenza vaccines, COVID-19 vaccines, inactivated poliovirus vaccine (IPV), and Mpox vaccine. Additionally, the schedule now includes recommendations for meningococcal serogroups A, B, C, W, and Y pentavalent vaccine (MenACWY-TT/MenB-FHbp). Any references to meningococcal serogroups A, C, W, and Y polysaccharide diphtheria toxoid conjugate vaccine (MenACWY-D, Menactra) have been removed, as this product is no longer distributed in the United States.
Furthermore, the changes encompass clarification of recommendations for hepatitis A (HAV), hepatitis B (HBV), human papillomavirus vaccine (HPV), measles, mumps, and rubella vaccine (MMR), pneumococcal vaccines, and tetanus, diphtheria, and pertussis vaccine (Tdap).
ACIP introduced a new detailed routine vaccination for RSV; maternal RSV vaccination during pregnancy, and a shared clinical decision voted to recommend that adults aged ≥60 years may receive a single dose of an RSV vaccine.
“RSV vaccines have demonstrated moderate to high efficacy in preventing RSV-associated lower respiratory tract disease and have the potential to prevent substantial morbidity and mortality among older adults; post-marketing surveillance will direct future guidance,” according to the CDC. 2
Recommendation Vaccinations for Ages 19 Years or Older
According to CDC, these are recommended vaccinations for adults who meet age requirements, lack documentation of vaccination, or lack evidence of immunity